BR0011741A - Compostos de organossilila tendo atividade de modulação do receptor de hormÈnio nuclear - Google Patents

Compostos de organossilila tendo atividade de modulação do receptor de hormÈnio nuclear

Info

Publication number
BR0011741A
BR0011741A BR0011741-2A BR0011741A BR0011741A BR 0011741 A BR0011741 A BR 0011741A BR 0011741 A BR0011741 A BR 0011741A BR 0011741 A BR0011741 A BR 0011741A
Authority
BR
Brazil
Prior art keywords
nuclear hormone
hormone receptor
modulating activity
receptor modulating
organosilyl compounds
Prior art date
Application number
BR0011741-2A
Other languages
English (en)
Inventor
Richard L Beard
Michael E Garst
Roshantha A Chandraratna
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Publication of BR0011741A publication Critical patent/BR0011741A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0805—Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms
    • C07F7/0807—Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms comprising Si as a ring atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "COMPOSTOS DE ORGANOSSILILA TENDO ATIVIDADE DE MODULAçãO DO RECEPTOR DE HORMÈNIO NUCLEAR". Compostos orgânicos contendo silício úteis como moduladores de receptores de hormónio nucleares de mamífero, particularmente os receptores retinóides e os receptores farnesóides,
BR0011741-2A 1999-06-11 2000-06-09 Compostos de organossilila tendo atividade de modulação do receptor de hormÈnio nuclear BR0011741A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13873199P 1999-06-11 1999-06-11
PCT/US2000/015972 WO2000077011A1 (en) 1999-06-11 2000-06-09 Organosilyl compounds having nuclear hormone receptor modulating activity

Publications (1)

Publication Number Publication Date
BR0011741A true BR0011741A (pt) 2002-03-19

Family

ID=22483369

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011741-2A BR0011741A (pt) 1999-06-11 2000-06-09 Compostos de organossilila tendo atividade de modulação do receptor de hormÈnio nuclear

Country Status (11)

Country Link
US (1) US6452032B1 (pt)
EP (1) EP1185539B1 (pt)
JP (1) JP2003502337A (pt)
CN (1) CN1368975A (pt)
AT (1) ATE283860T1 (pt)
AU (1) AU774538B2 (pt)
BR (1) BR0011741A (pt)
CA (1) CA2375797A1 (pt)
DE (1) DE60016404T2 (pt)
HK (1) HK1047752A1 (pt)
WO (1) WO2000077011A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144360A1 (en) * 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
PL206962B1 (pl) * 2001-12-19 2010-10-29 Bristol Myers Squibb Co Związek heterocykliczny o budowie skondensowanej
US6696473B2 (en) * 2001-12-21 2004-02-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
WO2004048391A1 (en) * 2002-11-25 2004-06-10 Amedis Pharmaceuticals Ltd. Silicon compounds to be used as ligands for retinoid receptors
US7618956B2 (en) * 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
PL3380086T3 (pl) 2015-11-25 2022-02-21 Io Therapeutics, Inc. Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu
EP3468600A4 (en) 2016-06-10 2019-11-13 IO Therapeutics, Inc. RETINOID COMPOUNDS AND RELECTIVE REXINOIDS OF THE RECEPTOR AND IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP3730487B1 (en) 2016-06-13 2022-04-27 Gilead Sciences, Inc. Azetidine derivatives as fxr (nr1h4) modulators
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
KR20200029544A (ko) 2017-07-13 2020-03-18 아이오 테라퓨틱스, 인크. 암 면역요법을 위해 면역 조절제와 조합된 면역조절 레티노이드 및 렉시노이드 화합물
SG11202001479RA (en) 2017-08-31 2020-03-30 Io Therapeutics Inc Rar selective agonists in combination with immune modulators for cancer immunotherapy
SI3911647T1 (sl) 2019-01-15 2024-04-30 Gilead Sciences, Inc. Izoksazolna spojina kot agonist FXR in farmacevtski sestavki, ki jo obsegajo
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588715A (en) * 1984-06-04 1986-05-13 Sandoz, Inc. Heptenoic acid derivatives
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5234926A (en) 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5162546A (en) 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5053523A (en) 1989-09-19 1991-10-01 Allergan, Inc. Ethynyl-chroman compounds
EP0577737A1 (en) 1991-03-26 1994-01-12 Allergan, Inc. Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity
US5134159A (en) 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
JP2856175B2 (ja) * 1996-10-25 1999-02-10 日本電気株式会社 液晶添加剤、液晶組成物およびそれを用いた液晶表示素子
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism

Also Published As

Publication number Publication date
DE60016404T2 (de) 2005-10-27
AU774538B2 (en) 2004-07-01
ATE283860T1 (de) 2004-12-15
EP1185539B1 (en) 2004-12-01
HK1047752A1 (zh) 2003-03-07
DE60016404D1 (de) 2005-01-05
CA2375797A1 (en) 2000-12-21
CN1368975A (zh) 2002-09-11
EP1185539A1 (en) 2002-03-13
AU5604000A (en) 2001-01-02
JP2003502337A (ja) 2003-01-21
US6452032B1 (en) 2002-09-17
WO2000077011A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
BR0011741A (pt) Compostos de organossilila tendo atividade de modulação do receptor de hormÈnio nuclear
CR6478A (es) Moduladores del receptor glucocorticoide
DE60336901D1 (de) Chinazolinon modulatoren von nukleinrezeptoren
ATE521599T1 (de) Heterocyclische modulatoren von nukleären rezeptoren
DE59807369D1 (de) Medizinische Bandage
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
DE60010098D1 (de) 28-epirapaloge
TR200003244T2 (tr) Yeni kullanım
MX9700696A (es) Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
WO2001077951A8 (en) System and methods for group retirement plan administration
ATE333678T1 (de) Netzwerkschalter und komponenten und betriebsverfahren
ATE261145T1 (de) Verfahren und vorrichtung zur ermittlung von benachbarten diensten
BR0110751A (pt) Dispositivo
BR0011743A (pt) Método para modular a atividade de receptor de fxr
BR0215058A (pt) 2-fenil benzofuranos substituìdos como agentes estrogênicos
ES2133727T3 (es) Derivados de acido hidroxamico como inhibidores de metaloproteinasa.
TR200002896T2 (tr) Kalsilitik Bileşimler
DK0874625T3 (da) Indanderivater til antipsykotiske præparater
ATE437853T1 (de) Glucocorticoid-rezeptoren-modulatoren
ATE277901T1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
TR199800152T1 (xx) Endotelin Resept�r Antagonistleri
ATE217619T1 (de) Endothelin-rezeptor-antagonisten
NO20021309D0 (no) Preparat for IVF
DE69903627D1 (de) Tetrahydroisochinolinderivate als modulatoren von dopamin d3 rezeptoren
NO20015378L (no) Cyklokarbamatderivater som progesteronreseptormodulatorer

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ALLERGAN SALES, LLC (US)

B25A Requested transfer of rights approved

Free format text: ALLERGAN, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.